CNDT · CONDUENT Inc
$1.60
-0.02 (-1.23%)
At close · Oct 7
Return incl. dividend (before tax)
Market Cap
$247.28M
Shares
155.52M
Volume · Oct 7
466.68K
Avg daily vol (3M)
993.58K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.60
Open$1.60
Day$1.59–1.62
52W close$1.16–2.77
Avg vol 30d1.1M
Short int5.3M · 3.4% float · 4.8d
Short vol20%
Last earningsAug 10, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 10, 2026
Est · unconfirmed
· in 5 wks
filed Aug 10, 2026
call held Aug 10, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$2.94B
Trailing 12 months
Net income (TTM)
−$228.00M
Trailing 12 months
Revenue growth YoY
-11.9%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-19.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$207.00M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-3.6%
Year over year · fewer shares
Price change (1Y)
-40.7%
Trailing year
Short interest
3.4%
Latest settlement · 4.8 days to cover
AI Brief
Q2 FY26 earnings call · Aug 10, 2026
Q2 FY26
TL;DR. Conduent reported Q2 revenue of $531M (down 11.9% Y/Y) and Adj. EBITDA of $16M (3.0% margin), announced the sale of its Transit and Tolling businesses for ~$234M gross proceeds, and recalibrated 2026 guidance to $2.15–$2.25B revenue and $140–$170M Adj. EBITDA excluding discontinued operations.
Bullish
- + Divestitures will reduce off-balance sheet financial instruments (surety bonds and letters of credit) by approximately 80%, leaving roughly $125M
- + Qualified new business pipeline grew to approximately $3B, up 11% year-over-year, with commercial pipeline up 48% since the beginning of 2026
- + First-half 2026 new business ACV signings of $188M equal prior year's first half, with 12% more annual recurring revenue signings and 7% more non-recurring revenue signings
- + Secured multi-year Virginia Medicaid renewal (~1.6M members) and implemented modernized New Mexico Medicaid platform (~900K members)
- + Adjusted free cash flow improved by $81M versus prior-year first half, primarily from achieving payment milestones
Bearish
- − Q2 revenue declined 11.9% Y/Y to $531M from $603M, driven by contract losses and lower volumes
- − Q2 Adjusted EBITDA fell to $16M from $23M and Adjusted EBITDA margin compressed 80 bps to 3.0%
- − Government segment Adjusted EBITDA margin declined 150 bps Y/Y to 23.7%, due to revenue impacts and favorable prior-year reserve releases
- − Commercial segment revenue declined 13% Y/Y, driven by loss of largest commercial client whose contract ends in Q3 2026
- − GAAP net loss from continuing operations widened to $(69)M from $(42)M Y/Y, driven by higher restructuring costs tied to transformation
- − Recalibrated full-year 2026 guidance to $2.15–$2.25B revenue and $140–$170M Adj. EBITDA on a continuing-operations basis, reflecting the impact of the divestitures
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.63
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+1%
above
Price vs 50-day avg
−2%
below
RSI (14)
47
neutral
MACD trend
Negative
52-week position
27%
mid-range
Momentum
relative strength
1-month return
+1%
trailing
6-month return
+1%
trailing
YTD return
−17%
this year
Relative strength
−10%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
2 of 191 funds reported for Sep 30 · net -224 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.42% of float · ▲ +17.2% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
191 holders — near 3-yr low, contrarian setup
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
−9%
Y/Y
Gross margin
34%
expanding
EPS growth
−151%
Y/Y
Free cash flow
$-132.0M
Buyback
$125.0M
authorized
Balance sheet
$458.0M
net debt
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
5.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 10, 2026
Revenue
· FY 2026
Initiated
$2.15B – $2.25B
prior FY $3.04B
midpoint −27.7% Y/Y
Adj. EBITDA from Continuing Operations
· FY 2026
Non-GAAP
Initiated
$140M – $170M
Guided vs delivered
· last 3 settled
Revenue
FY 2024
guided $3.6B – $3.7B
$3.36B
Miss −8.1%
Revenue
full-year 2021
guided $4.1B – $4.18B
$4.14B
In line
Revenue
quarter three
guided $960M – $1.01B
$1.04B
Beat +5.7%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+1%
Bullish
Price vs 50-day avg
−2%
Neutral
RSI (14)
47
Neutral
MACD trend
Negative
Bearish
52-week position
27%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
2 of 191 funds reported for Sep 30 · net -224 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.42% of float · ▲ +17.2% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
191 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $2 · 27%
Range high $3
vs 200-day avg +1%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Diluted EPS from Continuing Operations non-GAAP | -$0.18 | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Diluted EPS from Continuing Operations -$0.46
+$0.16 Total non-GAAP adjustments
+$0.12 Income tax adjustments
= Adjusted Diluted EPS from Continuing Operations -$0.18
|
|||
| Adjusted EBITDA non-GAAP | $16M | Q2 2026 | — |
| Adjusted EBITDA - Commercial non-GAAP | $24M | Q2 2026 | — |
| Adjusted EBITDA - Government non-GAAP | $51M | Q2 2026 | — |
| Adjusted EBITDA from Continuing Operations non-GAAP | $66M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA Margin non-GAAP | 3% | Three Months Ended June 30, 2026 filing | — |
| Adjusted EBITDA Margin from Continuing Operations non-GAAP | 5.9% | Six Months Ended June 30, 2026 | — |
| Adjusted Effective Tax Rate from Continuing Operations non-GAAP | 20.5% | Q2 2026 | — |
| Adjusted Free Cash Flow non-GAAP | -$8M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Free Cash Flow -$8M
+$3M Transaction costs
+$1M Direct response costs - cyber event payments
-$4M Vendor finance lease payments
= Adjusted Free Cash Flow -$8M
|
|||
| Adjusted Net Debt non-GAAP | $303M | June 30, 2026 | — |
| Adjusted Net Leverage Ratio non-GAAP | 2.1 | June 30, 2026 | — |
| Adjusted Operating Income from Continuing Operations non-GAAP | -$11M | Six Months Ended June 30, 2026 | — |
| Annual recurring revenue signings | $73M | Three Months Ended June 30, 2026 filing | — |
| Approximately 46,000 associates globally | 46,000 | Q2 2026 | — |
| Capex as % of revenue non-GAAP | 2.6% | Q2 2026 | — |
| Free Cash Flow | -$30M | Six Months Ended June 30, 2026 | — |
| Margin for Adjusted Operating Income from Continuing Operations non-GAAP | -3.8% | Q2 2026 | — |
| Medicaid members served (New Mexico platform) | 900,000 | Q2 2026 | — |
| New business ACV | $99M | Three Months Ended June 30, 2026 filing | — |
| New Business ACV Signings non-GAAP | $216M | Q2 2026 | — |
| New Business ACV Signings - Government non-GAAP | $51M | Q2 2026 | — |
| New Business NRR non-GAAP | $27M | Q2 2026 | — |
| New Business Signings ACV from Continuing Operations | $99M | Q2 2026 | — |
| New Business TCV Signings non-GAAP | $194M | Q2 2026 | — |
| Non-recurring revenue signings | $27M | Three Months Ended June 30, 2026 filing | — |
| Renewals TCV | $617M | Three Months Ended June 30, 2026 filing | — |
| Revenue at Constant Currency non-GAAP | $530M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Revenue 531M
-1M Foreign currency impact
= Revenue at Constant Currency 530M
|
|||
| Total Signings | $811M | Three Months Ended June 30, 2026 filing | — |
| Trailing 12 months Adjusted EBITDA from Continuing Operations non-GAAP | $141M | TTM June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Information Technology Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CNDT
this stock
CONDUENT Inc
|
$247.28M | -16.7% | -9.4% | — | 3.4% |
|
IBM
International Business Machines Corp
|
$207.75B | -25.6% | +7.6% | 19.5 | 2.4% |
|
ACN
Accenture plc
|
$131.32B | -26.7% | +7.4% | 15.7 | 3.7% |
|
INFY
Infosys Ltd
|
$42.73B | -40.8% | — | — | 3.1% |
|
CTSH
Cognizant Technology Solutions Corp
|
$27.26B | -31.2% | +7.0% | 12.5 | 7.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CNDT | +2.6% | +0.6% | +0.6% | +2.6% | -16.7% |
| SPY | +1.9% | +1.9% | +10.8% | +1.9% | +14.0% |
| vs SPY | +0.7% | -1.3% | -10.1% | +0.7% | -30.7% |
Capital returns
Buyback programs
· 2 active
· as of May 20, 2025
Authorized (total)
$125.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.